Marinus Interest Expense from 2010 to 2024
| MRNS Stock | USD 1.38 0.03 2.13% |
Interest Expense | First Reported 2012-12-31 | Previous Quarter 4.2 M | Current Value 4.3 M | Quarterly Volatility 1.4 M |
Check Marinus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Marinus main balance sheet or income statement drivers, such as Depreciation And Amortization of 523.5 K, Interest Expense of 17.7 M or Selling General Administrative of 63.5 M, as well as many exotic indicators such as Price To Sales Ratio of 17.91, Dividend Yield of 0.0 or PTB Ratio of 36.59. Marinus financial statements analysis is a perfect complement when working with Marinus Pharmaceuticals Valuation or Volatility modules.
Marinus | Interest Expense |
Latest Marinus Pharmaceuticals' Interest Expense Growth Pattern
Below is the plot of the Interest Expense of Marinus Pharmaceuticals over the last few years. It is the cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit. Marinus Pharmaceuticals' Interest Expense historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Marinus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Interest Expense | 10 Years Trend |
|
Interest Expense |
| Timeline |
Marinus Interest Expense Regression Statistics
| Arithmetic Mean | 3,377,047 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 185.72 | |
| Mean Deviation | 4,690,081 | |
| Median | 320,782 | |
| Standard Deviation | 6,271,689 | |
| Sample Variance | 39.3T | |
| Range | 17.7M | |
| R-Value | 0.72 | |
| Mean Square Error | 20.4T | |
| R-Squared | 0.52 | |
| Significance | 0 | |
| Slope | 1,010,113 | |
| Total Sum of Squares | 550.7T |
Marinus Interest Expense History
About Marinus Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Marinus Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Marinus Pharmaceuticals investors use historical funamental indicators, such as Marinus Pharmaceuticals's Interest Expense, to determine how well the company is positioned to perform in the future. Although Marinus Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Marinus Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Marinus Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Marinus Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Marinus Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Interest Expense | 16.9 M | 17.7 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Marinus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Marinus Pharmaceuticals' short interest history, or implied volatility extrapolated from Marinus Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Marinus Pharmaceuticals Correlation against competitors. For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Marinus Stock analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Marinus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marinus Pharmaceuticals. If investors know Marinus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marinus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.63) | Revenue Per Share 0.577 | Quarterly Revenue Growth 0.004 | Return On Assets (0.38) | Return On Equity (2.13) |
The market value of Marinus Pharmaceuticals is measured differently than its book value, which is the value of Marinus that is recorded on the company's balance sheet. Investors also form their own opinion of Marinus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Marinus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marinus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Marinus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Marinus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marinus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marinus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.